Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Keefe, Bruyette & Woods Downgrades Hercules Capital to Market Perform, Announces $18 Price Target
Keefe, Bruyette & Woods analyst Ryan Lynch downgrades Hercules Capital (NYSE:HTGC) from Outperform to Market Perform and announces $18 price target.
Hercules Cap: Q4 Earnings Insights
Hercules Cap (NYSE:HTGC) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Hercules Cap beat estimated earnings by 9.38%, reporting an EPS of $0.35 versus an estimate of $0.32.
Hercules Capital Q4 EPS $0.35 Beats $0.32 Estimate
Hercules Capital (NYSE:HTGC) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.32 by 9.37 percent. This is a 5.41 percent decrease over earnings of $0.37 per share from the
Earnings Scheduled For February 22, 2022
Companies Reporting Before The Bell
• Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million.
Compass Point Downgrades Hercules Cap to Neutral, Announces $18 Price Target
Compass Point analyst Casey Alexander downgrades Hercules Cap (NYSE:HTGC) from Buy to Neutral and announces $18 price target.
Stock Wars: Axsome Therapeutics Vs. Global Blood Therapeutics
Benzinga’s weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment.
Hercules Capital Surpasses $2B In Annual Gross Debt And Equity Commitments For First Time In History
Hercules Capital, Inc. (NYSE:HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some
Hercules Capital Q3 EPS $0.33, Inline, Sales $70.19M Beat $69.66M Estimate
Hercules Capital (NYSE:HTGC) reported quarterly earnings of $0.33 per share which met the analyst consensus estimate. This is a 2.94 percent decrease over earnings of $0.34 per share from the same period last year. The